好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Baseline Characteristics of Patients in the DEFINE Trial: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Study of BG-12 in Relapsing-Remitting Multiple Sclerosis
MS and Related Diseases
(-)
149
Authors/Disclosures
Haris Kamal, MD (University of Texas At Houston) Dr. Kamal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Microvention .
Kevin Messacar, MD No disclosure on file
Minhua Yang No disclosure on file